Advisers to the Food and Drug Administration recommended on Wednesday that children ages 5 to 11 receive the Pfizer-BioNTech vaccine.
The FDA's advisory committee announced the decision after a study found that the benefits for children who receive inoculation far outweigh the potential risks of cardiac arrest symptoms, according to the Washington Post.
The panel voted unanimously to support the Pfizer-BioNTech vaccine for children. Next, a group of advisers from the Centers for Disease Control and Prevention is expected to have a conference on Nov. 2 regarding the use of the vaccine for children, after which CDC Director Rochelle Walensky could give approval.
If given the go-ahead by the CDC chief, medical facilities will be able to dish out doses of the two-dose vaccine to children as early as the first week of November.
Pfizer and BioNTech submitted data to the FDA on Sept. 28 showcasing the effectiveness of the vaccine for children.
The trial study of 2,268 participants found that the vaccine "elicited robust neutralizing antibody response" in the children. After this, Pfizer filed an application with the FDA for emergency use authorization of its vaccine.
In August, the Pfizer-BioNTech vaccine received full approval of its two-dose vaccine for people ages 16 and older. After receiving full approval of the vaccine, on Oct. 22 the FDA released a study from Pfizer and BioNTech which showed the effectiveness of the vaccine.
The companies reported the vaccine was over 90% effective in protecting children ages 5 to 11 against COVID-19.
Roughly 58.9% of the people in the United States between the ages of 12 and 17 have received their first dose of a coronavirus vaccine, with 49.1% receiving a second dose or being considered to be fully vaccinated, according to data from Mayo Clinic. Two-thirds of people across the U.S., 66.7%, have received their first dose while 57.7% have received a second dose or are considered to be fully vaccinated
Washington Examiner Videos
Original Author: Elizabeth Faddis
Original Location: FDA advisers recommend Pfizer vaccine for children ages 5 to 11